Clinuvel Pharmaceuticals Ltd
ASX:CUV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Glory Mark Hi-Tech (Holdings) Ltd
HKEX:8159
|
HK |
|
Gan Yuan Foods Co Ltd
SZSE:002991
|
CN |
|
T
|
Transmit Entertainment Ltd
HKEX:1326
|
HK |
Clinuvel Pharmaceuticals Ltd
Total Current Liabilities
Clinuvel Pharmaceuticals Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Current Liabilities
AU$17.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
22%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Current Liabilities
$128.1m
|
CAGR 3-Years
33%
|
CAGR 5-Years
7%
|
CAGR 10-Years
12%
|
|
|
CSL Ltd
ASX:CSL
|
Total Current Liabilities
$4.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Current Liabilities
AU$1.2m
|
CAGR 3-Years
11%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Current Liabilities
AU$231.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Current Liabilities
AU$11m
|
CAGR 3-Years
11%
|
CAGR 5-Years
57%
|
CAGR 10-Years
29%
|
|
Clinuvel Pharmaceuticals Ltd
Glance View
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
See Also
What is Clinuvel Pharmaceuticals Ltd's Total Current Liabilities?
Total Current Liabilities
17.9m
AUD
Based on the financial report for Dec 31, 2025, Clinuvel Pharmaceuticals Ltd's Total Current Liabilities amounts to 17.9m AUD.
What is Clinuvel Pharmaceuticals Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
22%
Over the last year, the Total Current Liabilities growth was 36%.
